The combination of ABT-737 with chemotherapeutic agents [42,43,44] or other targeted therapy molecules [45,46] has synergistic efficacy and is a promising molecule for treating BCL-2 dependent solid tumors and hematologic malignancies [47]. This evidence concerns the gene BCL2 and hematologic disorder.